Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome

Journal of Thrombosis and Thrombolysis

Volumn 44, Issue 3, 2017, Pages 355-361

  Toso, Anna ^a   De Servi, Stefano ^b   Leoncini, Mario ^a   Angiolillo, Dominick J ^c   Calabrò, Paolo ^d   Piscione, Federico ^e   Cattaneo, Marco ^f   Maffeo, Diego ^g   Bartorelli, Antonio ^h   Palmieri, Cataldo ⁱ   De Carlo, Marco ^j   Capodanno, Davide ^k   Genereux, Philippe ^l,m,n   Bellandi, Francesco ^a   Barozzi, Chiara ^o   Tomasi, Luciana ^o   Della Riva, Diego ^o   Palmerini, Tullio ^o  

^a Santo Stefano Hospital   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e S Giovanni di Dio e Ruggi d'Aragona Hospital   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g Fondazione Poliambulanza Istituto Ospedaliero   (Italy)

^h IRCCS   (Italy)

ⁱ Heart Hospital   (Italy)

^j UNIVERSITY HOSPITAL OF PISA   (Italy)

^k UNIVERSITY OF CATANIA   (Italy)

^l CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^m Gagnon Cardiovascular Institute   (United States)

ⁿ HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^o UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

Acute coronary syndrome; Clopidogrel; High platelet reactivity; Pharmacodynamics; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; VASODILATOR STIMULATED PHOSPHOPROTEIN; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFECT; DRUG POTENTIATION; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYNTAX SCORE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; MIDDLE AGED; THROMBOCYTE ACTIVATION; VERY ELDERLY;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET ACTIVATION; TICLOPIDINE;

EID: 85028321794     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-017-1541-x     Document Type: Article

References (29)

1. Brar SS, ten Berg J, Marcucci M et al (2011) Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: a collaborative meta-analysis of individual participant data. J Am Coll Cardiol 58:1945–1954
2. Campo G, Parrinello G, Ferraresi P et al (2011) Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention. Relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 57:2474–2483
3. Amsterdam EA, Wenger NK, Brindis RG et al (2014) 2014 AHA/ACC guideline for the management of patients with non–st-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 64:e139-e228
4. Roffi M, Patrono C, Collet JP et al (2015) 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent STsegment elevation of the European Society of Cardiology (ESC). Eur Heart J 37:267–315
5. Rosenson RS, Kent ST, Brown TM et al (2015) Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. J Am Coll Cardiol 65:270–277
6. Eisen A, Cannon CP, Braunwald E et al (2017) Predictors of nonuse of a high-potency statin after an acute coronary syndrome: insights from the stabilization of plaques using darapladib-thrombolysis in myocardial infarction 52 (SOLID-TIMI 52) trial. J Am Heart Assoc 6:e004332
7. Davidson MH (2005) Clinical significance of statin pleiotropic effects hypotheses versus evidence. Circulation 111:2280–2281
8. Violi F, Calvieri C, Ferro D, Pignatelli P (2013) Statins as antithrombotic drugs. Circulation 127:251–257
9. Piorkowski M, Fischer S, Stellbaum C et al (2007) Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J Am Col Cardiol 49:1035–1042
10. Leoncini M, Toso A, Maioli M et al (2013) High-Dose atorvastatin on the pharmacodynamics effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: the ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study. J Am Coll Cardiol Intv 6:169–179
11. Palmerini T, Calabrò P, Piscione F et al (2014) Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study. J Am Coll Cardiol Intv 7:1117–1127
12. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C (2005) Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 3:85–92
13. Tantry US, Bonello L, Aradi D et al (2013) Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62:2261–2271
14. Stone NJ, Robinson JG, Lichtenstein AH et al (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol 63:2889–2934
15. Giusti B, Abbate R (2010) Response to antiplatelet treatment: from genes to outcome. Lancet 376:1278–1281
16. Matetzky S, Fefer P, Shenkman B et al (2011) Statins have an early antiplatelet effect in patients with acute myocardial infarction. Platelets 22:103–110
17. Bates ER, Lau WC, Angiolillo DJ (2011) Clopidogrel–drug interactions. J Am Coll Cardiol 57:1251–1263
18. Bonello L, Tantry US, Marcucci R et al (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919–933
19. Mukherjee D, Kline-Rogers E, Fang J, Munir K, Eagle KA (2005) Lack of clopidogrel–CYP3A4 statin interaction in patients with acute coronary syndrome. Heart 91:23–26
20. Ojeifo O, Wiviott D, Antman EM et al (2013) Concomitant administration of clopidogrel with statins or calcium-channel blockers. Insights from the TRITON–TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel–thrombolysis in myocardial infarction 38). J Am Coll Cardiol Intv 6:1275–1281
21. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2007) Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49:1505–1516
22. Capodanno D, Angiolillo DJ (2012) Antithrombotic therapy in patients with chronic kidney disease. Circulation 125:2649–2661
23. Morel O, Muller C, Jesel L, Moulin B, Hannedouche T (2013) Impaired platelet P2Y12 inhibition by thienopyridines in chronic kidney disease: mechanisms, clinical relevance and pharmacological options. Nephrol Dial Transplant 28:1994–2002
24. Angiolillo DJ, Jakubowski JA, Ferreiro J et al (2014) Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll Cardiol 64:1005–1014
25. Capodanno D, Angiolillo DJ (2010) Antithrombotic therapy in the elderly. J Am Coll Cardiol 56:1683–1692
26. Kurlansky P, Herbert M, Prince S et al (2016) Coronary artery bypass graft versus percutaneous coronary intervention: meds matter: impact of adherence to medical therapy on comparative outcomes. Circulation 134:1238–1246
27. Windecker S, Kolh P, Alfonso F et al (2014) 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 35:2541–2619
28. Zeymer U, Widimsky P, Danchin N et al (2016) P2Y12 receptor inhibitors in patients with non-ST elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries. Eur Heart J Cardiovasc Pharmacother 2:229–243
29. Fan W, Plent S, Prats J, Deliargyris EN (2016) Trends in P2Y12 inhibitor use in patients referred for invasive evaluation of coronary artery disease in contemporary US practice. Am J Cardiol 117:1439–1443